← Back to Clinical Trials
Recruiting NCT07408154

NCT07408154 Direct vs Standard SLT for Glaucoma: A Noninferiority Trial

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07408154
Status Recruiting
Phase
Sponsor Medical University of South Carolina
Condition Open-angle Glaucoma (OAG)
Study Type INTERVENTIONAL
Enrollment 172 participants
Start Date 2026-04-27
Primary Completion 2027-10

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Direct Selective laser Trabeculoplasty

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 172 participants in total. It began in 2026-04-27 with a primary completion date of 2027-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study compares two FDA-approved laser treatments for glaucoma: Direct Selective Laser Trabeculoplasty (DSLT) and Selective Laser Trabeculoplasty (SLT). Both procedures aim to lower eye pressure and prevent vision loss. DSLT is a newer, non-contact technique that may improve comfort and efficiency. Participants will be randomly assigned to receive either DSLT or SLT and followed for 12 months to assess eye pressure, safety, and treatment outcomes.

Eligibility Criteria

Inclusion Criteria: * Age ≥18 years * Diagnosis of OAG (including exfoliative or pigmentary) or OHT * Gonioscopically open angle (visible scleral spur 360°) * Ability to consent and comply with follow-up Exclusion Criteria: * Angle-closure or secondary glaucomas * IOP \>35 mmHg despite therapy * Corneal pathology interfering with laser or IOP measurement * Recent ocular surgery (\<6 months) * Contraindications to study medications or procedures * Cognitive impairment preventing consent

Contact & Investigator

Principal Investigator

Jella An, MD

PRINCIPAL INVESTIGATOR

Medical University of South Carolina

Frequently Asked Questions

Who can join the NCT07408154 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Open-angle Glaucoma (OAG). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07408154 currently recruiting?

Yes, NCT07408154 is actively recruiting participants. Visit ClinicalTrials.gov or contact Medical University of South Carolina to inquire about joining.

Where is the NCT07408154 trial being conducted?

This trial is being conducted at Charleston, United States.

Who is sponsoring the NCT07408154 clinical trial?

NCT07408154 is sponsored by Medical University of South Carolina. The principal investigator is Jella An, MD at Medical University of South Carolina. The trial plans to enroll 172 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology